COPD Trial, Recruiting NCT06480604 Sponsor: The Archer-Daniels-Midland Company Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT06480604
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman who has not yet reached menopause, aged between 18 and 50 years
  • You have a current vaginal yeast infection caused by Candida (confirmed by a lab test within 24–48 hours of your symptoms starting, and before any treatment was started)
  • You have had at least 3 vaginal yeast infections in the past 12 months, confirmed by a lab test or a doctor's diagnosis
  • Your yeast infection has been confirmed by a vaginal swab culture showing Candida growth
  • Your random blood sugar level is below 110 mg/dl
  • You are willing to use the study products for the full length of the study
  • You are willing to complete all required study visits and follow the study rules
  • You are willing to avoid taking other supplements or medications during the study
  • You are willing to sign a written consent form agreeing to take part in the study

Who may not be able to join:

  • You are going through or have already gone through menopause
  • You are pregnant or currently breastfeeding
  • You have used antifungal medication (by mouth or vaginally) in the last 14 days
  • Your vaginal swab test shows a different type of infection, such as bacterial vaginosis, trichomonas, or Gardnerella (confirm with trial site)
  • Your lab results show that your yeast infection does not respond to the antifungal medication used in this study (Clotrimazole)
  • You have a known allergy to Clotrimazole (a common antifungal medication)
  • You are not willing to use vaginal medication during the study
  • You use vaginal douching products
  • You are unwilling to use a suitable form of contraception during the study
  • You have been diagnosed with a weakened immune system, Type 1 or Type 2 diabetes, or any form of cancer
  • You have used steroid medications in the last 30 days
  • You have taken antibiotic or other antimicrobial medications by mouth or otherwise in the last 30 days
  • You have a known allergy to the study products or a group of antifungal medicines called azoles
  • You have a history of getting frequent infections that repeatedly required antibiotic treatment
  • You have taken part in another clinical trial in the last 3 months
  • In the trial doctor's opinion, you may have difficulty attending appointments or following the study requirements
  • You have high blood pressure that is not well controlled (top number 140 or above, and/or bottom number 90 or above)
  • You drink alcohol heavily — for women, this means more than 3 drinks on any single day or more than 7 drinks per week
  • You are a smoker
  • You have a significant ongoing condition affecting your kidneys, liver, hormones, digestive system, pancreas, or nervous system that the trial doctor believes could interfere with the study or put you at risk (confirm with trial site)
  • You have an unstable, rapidly worsening, or life-threatening illness
  • You have used any supplements in the last 30 days, including probiotics, herbal supplements, vitamins with probiotics, or similar products

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +441460243230

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Archer-Daniels-Midland Company
Registry
ClinicalTrials.gov
Start date
15 October 2024
Est. completion
1 July 2025

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Incidence of culture-confirmed VVC recurrence between baseline and day 180 as compared to placebo.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov